FDA Clearance Tracker · K181443
Accula RSV Test
Last checked: Nov 20, 2026Latest source record: Nov 23, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Nov 23, 2018
Substantially Equivalent
Time to decision
176 days
Received May 31, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K181443
- Device name
- Accula RSV Test
- Applicant
- Mesa Biotech, Inc.
- Applicant location
- San Diego, CA
- Received
- May 31, 2018
- Decided
- Nov 23, 2018
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3980
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OCC. The earliest in FDA's data is DEN070013, decided Jan 3, 2008.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K181443
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Mesa Biotech, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Accula Strep A Test510(k)
K201269 · Decided Nov 9, 2020 · 181 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
- Accula Flu A/Flu B Test510(k)
K171641 · Decided Feb 6, 2018 · 249 days after receipt
Device type: Influenza A And Influenza B Multiplex Nucleic Acid Assay (OZE) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.